|
|
继发性未分化甲状腺癌1例及基因分析
|
Abstract:
患者男性，84岁，以进行性吞咽困难起病，入院后术后病理提示甲状腺乳头状癌与未分化癌并存，在临床上较为罕见。
A patient, 84 years old, with progressive dysphagia, was diagnosed as coexistence of papillary thyroid carcinoma and differentiated carcinoma through postoperative pathology, which is rare in clinical cases.
| [1] | National Health Commission of the People’s Republic of China Medical Administration and Hospital Administration. 甲状腺癌诊疗指南(2022年版) [J]. 中国实用外科杂志, 2022, 42(12): 1343-1357, 1363. |
| [2] | Zheng, R.S., Sun, K.X., Zhang, S.W., Zeng, H.M., Zou, X.N., Chen, R., et al. (2019) Report of Cancer Epidemiology in China, 2015. Chinese Journal of Oncology, 41, 19-28. |
| [3] | Xing, M. (2013) Molecular Pathogenesis and Mechanisms of Thyroid Cancer. Nature Reviews Cancer, 13, 184-199. https://doi.org/10.1038/nrc3431 |
| [4] | 赵晓文, 钱震, 朱萌, 等. 未分化甲状腺癌1例临床病理特征报道[J]. 诊断病理学杂志, 2022, 29(2): 177-178. |
| [5] | Deeken-Draisey, A., Yang, G., Gao, J. and Alexiev, B.A. (2018) Anaplastic Thyroid Carcinoma: An Epidemiologic, Histologic, Immunohistochemical, and Molecular Single-Institution Study. Human Pathology, 82, 140-148. https://doi.org/10.1016/j.humpath.2018.07.027 |
| [6] | Prior, I.A., Hood, F.E. and Hartley, J.L. (2020) The Frequency of Ras Mutations in Cancer. Cancer Research, 80, 2969-2974. https://doi.org/10.1158/0008-5472.can-19-3682 |
| [7] | Lai, W., Liu, C., Lin, S., Chen, C. and Hang, J. (2020) Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors. Cancers, 12, Article 1973. https://doi.org/10.3390/cancers12071973 |
| [8] | Pozdeyev, N., Rose, M.M., Bowles, D.W. and Schweppe, R.E. (2020) Molecular Therapeutics for Anaplastic Thyroid Cancer. Seminars in Cancer Biology, 61, 23-29. https://doi.org/10.1016/j.semcancer.2020.01.005 |
| [9] | Shi, X., Liu, R., Qu, S., Zhu, G., Bishop, J., Liu, X., et al. (2015) Association of TERT Promoter Mutation 1,295,228 C>T with BRAF V600E Mutation, Older Patient Age, and Distant Metastasis in Anaplastic Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 100, E632-E637. https://doi.org/10.1210/jc.2014-3606 |
| [10] | Untch, B.R., Dos Anjos, V., Garcia-Rendueles, M.E.R., Knauf, J.A., Krishnamoorthy, G.P., Saqcena, M., et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 78, 4642-4657. https://doi.org/10.1158/0008-5472.can-17-1925 |
| [11] | Garcia-Rendueles, M.E.R., Ricarte-Filho, J.C., Untch, B.R., Landa, I., Knauf, J.A., Voza, F., et al. (2015) NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discovery, 5, 1178-1193. https://doi.org/10.1158/2159-8290.cd-15-0330 |
| [12] | 王月华, 常苗苗, 王芳, 等. 原发性甲状腺非霍奇金淋巴瘤12例临床病理分析[J]. 临床与实验病理学杂志, 2019, 35(8): 957-958, 961. |
| [13] | Wells, S.A., Asa, S.L., Dralle, H., Elisei, R., Evans, D.B., Gagel, R.F., et al. (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 25, 567-610. https://doi.org/10.1089/thy.2014.0335 |
| [14] | 黄勇杰, 李炳权, 罗丽花, 等. 甲状腺髓样癌5例临床病理分析[J]. 安徽医药, 2022, 26(1): 161-164. |
| [15] | Ciampi, R., Romei, C., Pieruzzi, L., Tacito, A., Molinaro, E., Agate, L., et al. (2016) Classical Point Mutations of RET, BRAF and RAS Oncogenes Are Not Shared in Papillary and Medullary Thyroid Cancer Occurring Simultaneously in the Same Gland. Journal of Endocrinological Investigation, 40, 55-62. https://doi.org/10.1007/s40618-016-0526-5 |
| [16] | 张炳洲, 张波林, 张维, 等. 甲状腺血管肉瘤的诊断和治疗进展[J]. 中国现代手术学杂志, 2023, 27(3): 242-247. |
| [17] | Bible, K.C., Kebebew, E., Brierley, J., Brito, J.P., Cabanillas, M.E., Clark, T.J., et al. (2021) 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 31, 337-386. https://doi.org/10.1089/thy.2020.0944 |
| [18] | Tashima, L., Mitzner, R., Durvesh, S. and Goldenberg, D. (2011) Dyspnea as a Prognostic Factor in Anaplastic Thyroid Carcinoma. European Archives of Oto-Rhino-Laryngology, 269, 1251-1255. https://doi.org/10.1007/s00405-011-1762-0 |
| [19] | Wagle, N., Grabiner, B.C., Van Allen, E.M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., et al. (2014) Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. New England Journal of Medicine, 371, 1426-1433. https://doi.org/10.1056/nejmoa1403352 |
| [20] | Naing, A., Gainor, J.F., Gelderblom, H., Forde, P.M., Butler, M.O., Lin, C., et al. (2020) A First-in-Human Phase 1 Dose Escalation Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. Journal for ImmunoTherapy of Cancer, 8, e000530. https://doi.org/10.1136/jitc-2020-000530 |
